Platelet Derived Growth Factor in Treatment of Chronic Non Healing Ulcer: A 10 Year Journey
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.168 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Seema Shah und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Chronic non-healing ulcers are a significant global healthcare burden, affecting about 8.2 million Medicare beneficiaries in the US, and costing an annual treatment cost of $28.1 to $96.8 billion annually. Platelet derived growth factor (PDGF) is a crucial hormone in wound healing that induces cell proliferation, angiogenesis, and extracellular matrix formation. This systematic review aims to assess the efficacy and safety of PDGF therapy versus placebo/usual care for chronic non-healing ulcers in the last 10 years.
Methods
Systematic review according to the PRISMA 2020 statement by searching PubMed/MEDLINE, Scopus, Web of Science Cochrane Central Register of Controlled Trials and Embase from January 2015 to December 2024. Eligible studies were randomized controlled trials, cohort studies and case-control studies in adult patients with chronic non healing ulcers receiving PDGF preparations. The main outcome measures were complete healing rates, time to healing, ulcer area reduction and adverse events. The Cochrane Risk of Bias Tool was used for quality assessment.
Results
There were 28 studies totaling 4,118 patients, including 3 retrospective cohorts, 7 prospective cohorts, and 18 randomized controlled trials. The majority of research concentrated on diabetic foot ulcers (71.4%), which were followed by pressure ulcers (10.7%) and venous leg ulcers (17.9%). When compared to standard care, platelet-derived growth factor (PDGF) dramatically increased healing rates, especially in venous leg ulcers (OR: 5.06) and diabetic foot ulcers (OR: 1.53). Additionally, PDGF increased the reduction of ulcer size and reduced the healing time by three to six weeks.
Conclusion
PDGF therapy appears to be an effective and safe adjunctive treatment for chronic non-healing ulcers, particularly diabetic foot ulcers and venous leg ulcers. Its use is associated with improved healing rates, shorter healing time, and greater reduction in ulcer area compared with standard care. Future studies should focus on evaluating long-term outcomes, assessing cost-effectiveness, and identifying patient-specific predictors of treatment response in order to optimize its clinical use.
Zitieren
APA
Shah, S., Verma, N. R., Verma, S., Patel, S., Nanda, R., & Mohapatra, E. (2026). Platelet Derived Growth Factor in Treatment of Chronic Non Healing Ulcer: A 10 Year Journey. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.168
Vancouver
Shah S, Verma NR, Verma S, Patel S, Nanda R, Mohapatra E. Platelet Derived Growth Factor in Treatment of Chronic Non Healing Ulcer: A 10 Year Journey. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.168
BibTeX
@article{Shah2026,
author = {Shah, Seema and Verma, Neha Rani and Verma, Shradha and Patel, Suprava and Nanda, Rachita and Mohapatra, Eli},
title = {Platelet Derived Growth Factor in Treatment of Chronic Non Healing Ulcer: A 10 Year Journey},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.168}
}
EUVIMED